A A

Dr. A A

Amsterdam UMC, Vrije Universiteit, Department of Neurosurgery, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AAA A
A A
SRSantiago Gil Robles
Santiago Gil Robles
AZAeilko H. Zwinderman
Aeilko H. Zwinderman
HDHugues Duffau
Hugues Duffau
MBMitchel S. Berger
Mitchel S. Berger
Purpose: Surgery for infiltrative gliomas aims to balance tumor removal with preservation of functional integrity. The usefulness of intraoperative stimulation mapping (ISM) has not been addressed in randomized trials. This study addresses glioma surgery outcome on the basis of a meta-analysis of observational studies. Methods: A systematic search retrieved 90 reports published between 1990 and 2010 with 8,091 adult patients who had resective surgery for supratentorial infiltrative glioma, with or without ISM. Quality criteria consisted of postoperative neurologic examination details and follow-up timing. New postoperative neurologic deficits were categorized on the basis of timing and severity. Meta-analysis with a Bayesian random effects model determined summary event rates of deficits as well as gross total resection rate and eloquent locations. Meta-regression analysis explored heterogeneity among studies. Results: Late severe neurologic deficits were observed in 3.4% (95% CI, 2.3% to 4.8%) of patients after resections with ISM, and in 8.2% (95% CI, 5.7% to 11.4%) of patients after resections without ISM (adjusted odds ratio, 0.39; 95% CI, 0.23 to 0.64). The percentages of radiologically confirmed gross total resections were 75% (95% CI, 66% to 82%) with ISM and 58% (95% CI, 48% to 69%) without ISM. Eloquent locations were involved in 99.9% (95% CI, 99.9% to 100%) of resections with ISM and in 95.8% (95% CI, 73.1% to 99.8%) of resections without ISM. Relevant sources of heterogeneity among studies were ISM, continent, and academic setting. Conclusion: Glioma resections using ISM are associated with fewer late severe neurologic deficits and more extensive resection, and they involve eloquent locations more frequently. This indicates that ISM should be universally implemented as standard of care for glioma surgery.

6 October 2021 in Nature
Verified
Journal Article
Open access
PDF file
JBJim Berg
Jim Berg
SSStaci A. Sorensen
Staci A. Sorensen
JTJonathan T. Ting
Jonathan T. Ting
JMJeremy Miller
Jeremy Miller
TCThomas Chartrand
Thomas Chartrand
ELEd S. Lein
Ed S. Lein
The neocortex is disproportionately expanded in human compared with mouse1,2, both in its total volume relative to subcortical structures and in the proportion occupied by supragranular layers composed of neurons that selectively make connections within the neocortex and with other telencephalic structures. Single-cell transcriptomic analyses of human and mouse neocortex show an increased diversity of glutamatergic neuron types in supragranular layers in human neocortex and pronounced gradients as a function of cortical depth3. Here, to probe the functional and anatomical correlates of this transcriptomic diversity, we developed a robust platform combining patch clamp recording, biocytin staining and single-cell RNA-sequencing (Patch-seq) to examine neurosurgically resected human tissues. We demonstrate a strong correspondence between morphological, physiological and transcriptomic phenotypes of five human glutamatergic supragranular neuron types. These were enriched in but not restricted to layers, with one type varying continuously in all phenotypes across layers 2 and 3. The deep portion of layer 3 contained highly distinctive cell types, two of which express a neurofilament protein that labels long-range projection neurons in primates that are selectively depleted in Alzheimer’s disease4,5. Together, these results demonstrate the explanatory power of transcriptomic cell-type classification, provide a structural underpinning for increased complexity of cortical function in humans, and implicate discrete transcriptomic neuron types as selectively vulnerable in disease.

1 September 2010 in Cancer Cell
Verified
Journal Article
Closed access
SMShahryar E. Mir
Shahryar E. Mir
AAA A
A A
PKPrzemek M. Krawczyk
Przemek M. Krawczyk
Leonora BalajLeonora Balaj
Leonora Balaj
ACAn Claes
An Claes
TWThomas Würdinger
Thomas Würdinger

16 March 2012 in Brain Structure and Function
Verified
Journal Article
Closed access
PDF file
JMJuan Martino
Juan Martino
AAA A
A A
MBMitchel S. Berger
Mitchel S. Berger
MLMichael T. Lawton
Michael T. Lawton
CAChristine M. Arnold
Christine M. Arnold
HDHugues Duffau
Hugues Duffau

1 July 2011 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AAA A
A A
SMShahryar E. Mir
Shahryar E. Mir
DNDavid Noske
David Noske
CNCornelis J.F. Van Noorden
Cornelis J.F. Van Noorden
TWTom Würdinger
Tom Würdinger
WEE1 kinase is a key molecule in maintaining G2–cell-cycle checkpoint arrest for premitotic DNA repair. Whereas normal cells repair damaged DNA during G1-arrest, cancer cells often have a deficient G1-arrest and largely depend on G2-arrest. The molecular switch for the G2–M transition is held by WEE1 and is pushed forward by CDC25. WEE1 is overexpressed in various cancer types, including glioblastoma and breast cancer. Preclinical studies with cancer cell lines and animal models showed decreased cancer cell viability, reduced tumor burden, and improved survival after WEE1 inhibition by siRNA or small molecule inhibitors, which is enhanced by combination with conventional DNA-damaging therapy, such as radiotherapy and/or cytostatics. Mitotic catastrophe results from premature entry into mitosis with unrepaired lethal DNA damage. As such, cancer cells become sensitized to conventional therapy by WEE1 inhibition, in particular those with insufficient G1-arrest due to deficient p53 signaling, like glioblastoma cells. One WEE1 inhibitor has now reached clinical phase I studies. Dose-limiting toxicity consisted of hematologic events, nausea and/or vomiting, and fatigue. The combination of DNA-damaging cancer therapy with WEE1 inhibition seems to be a rational approach to push cancer cells in mitotic catastrophe. Its safety and efficacy are being evaluated in clinical studies. Clin Cancer Res; 17(13); 4200–7. ©2011 AACR.

11 October 2023 in Nature
Verified
Journal Article
Open access
PDF file
CVC. Vermeulen
C. Vermeulen
MPMarc Pagès-Gallego
Marc Pagès-Gallego
LKL. Kester
L. Kester
MKMariette Kranendonk
Mariette Kranendonk
PWP. Wesseling
P. Wesseling
JRJeroen de Ridder
Jeroen de Ridder
Central nervous system tumours represent one of the most lethal cancer types, particularly among children1. Primary treatment includes neurosurgical resection of the tumour, in which a delicate balance must be struck between maximizing the extent of resection and minimizing risk of neurological damage and comorbidity2,3. However, surgeons have limited knowledge of the precise tumour type prior to surgery. Current standard practice relies on preoperative imaging and intraoperative histological analysis, but these are not always conclusive and occasionally wrong. Using rapid nanopore sequencing, a sparse methylation profile can be obtained during surgery4. Here we developed Sturgeon, a patient-agnostic transfer-learned neural network, to enable molecular subclassification of central nervous system tumours based on such sparse profiles. Sturgeon delivered an accurate diagnosis within 40 minutes after starting sequencing in 45 out of 50 retrospectively sequenced samples (abstaining from diagnosis of the other 5 samples). Furthermore, we demonstrated its applicability in real time during 25 surgeries, achieving a diagnostic turnaround time of less than 90 min. Of these, 18 (72%) diagnoses were correct and 7 did not reach the required confidence threshold. We conclude that machine-learned diagnosis based on low-cost intraoperative sequencing can assist neurosurgical decision-making, potentially preventing neurological comorbidity and avoiding additional surgeries.